Skip to main content
Article thumbnail
Location of Repository

The role of tau in neurodegeneration

By Tania F Gendron and Leonard Petrucelli


Since the identification of tau as the main component of neurofibrillary tangles in Alzheimer's disease and related tauopathies, and the discovery that mutations in the tau gene cause frontotemporal dementia, much effort has been directed towards determining how the aggregation of tau into fibrillar inclusions causes neuronal death. As evidence emerges that tau-mediated neuronal death can occur even in the absence of tangle formation, a growing number of studies are focusing on understanding how abnormalities in tau (e.g. aberrant phosphorylation, glycosylation or truncation) confer toxicity. Though data obtained from experimental models of tauopathies strongly support the involvement of pathologically modified tau and tau aggregates in neurodegeneration, the exact neurotoxic species remain unclear, as do the mechanism(s) by which they cause neuronal death. Nonetheless, it is believed that tau-mediated neurodegeneration is likely to result from a combination of toxic gains of function as well as from the loss of normal tau function. To truly appreciate the detrimental consequences of aberrant tau function, a better understanding of all functions carried out by tau, including but not limited to the role of tau in microtubule assembly and stabilization, is required. This review will summarize what is currently known regarding the involvement of tau in the initiation and development of neurodegeneration in tauopathies, and will also highlight some of the remaining questions in need of further investigation

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2009). a novel family of protein kinases that phosphorylateMolecular Neurodegeneration
  2. A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.
  3. (2002). A: Tau is essential to beta-amyloid-induced neurotoxicity.
  4. (1997). Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubuleassociated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. P r o c N a t l A c a d S c i U S A
  5. (2005). Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
  6. (2004). Akaike A, Shimohama S: Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons. Brain Res
  7. (2006). al.: An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA
  8. (1986). Alafuzoff I, Winblad B: Defective brain microtubule assembly in Alzheimer's disease. Lancet
  9. (1994). Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature
  10. (1994). Analysis of microtubuleassociated protein tau glycation in paired helical filaments.
  11. (1997). Anderton BH: Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly.
  12. (1996). Anderton BH: Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience
  13. (2002). Anderton BH: Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases.
  14. (1997). Appel SH: Beta-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of beta-amyloid precursor protein.
  15. (1999). Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet
  16. (2004). Atwood CS: Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.
  17. (2000). Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol
  18. (2004). B: PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell
  19. (2006). Bahr BA: 3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism. Hippocampus
  20. (2005). Betasecretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease.
  21. (2003). Biological selectivity and functional aspects of protein tyrosine nitration.
  22. (1995). Braak E: Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging
  23. (1992). BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology
  24. (2006). BT: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.
  25. (2006). C-terminal truncation modulates both nucleation and extension phases of tau fibrillization.
  26. (1987). Cadete-Leite A: A quantitative study of frontal cortex dendritic microtubules in patients with Alzheimer's disease. Brain Res
  27. (2003). Caillet-Boudin ML: Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins – a role in nuclear localization. Biochim Biophys Acta
  28. (2006). Canu N: NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA
  29. (2005). Cattaneo A: Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J Alzheimers Dis
  30. (2000). Cattaneo A: The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis.
  31. (1996). CC: Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation.
  32. (2003). Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron
  33. (2005). Cellcycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.
  34. (2006). Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology
  35. (1989). Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.
  36. (1997). Co-localization of truncated tau and DNA fragmentation in Alzheimer's disease neurones. Neuroreport
  37. (2008). Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathol Appl Neurobiol
  38. (2001). Cortical synapse loss in progressive supranuclear palsy.
  39. (2004). Cotman CW: Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.
  40. (1999). Delacourte A: Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol
  41. (2006). Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.
  42. (2003). Differential regulation of microtubule dynamics by three- and fourrepeat tau: implications for the onset of neurodegenerative disease.
  43. (2005). Disease-related modifications in tau affect the interaction between Fyn and Tau.
  44. (2005). DP: Molecular motors implicated in the axonal transport of tau and alphasynuclein.
  45. (2008). DP: Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. Faseb J
  46. (2003). DW: Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
  47. (2004). E: Mitochondrial impairment induces excitotoxic death in cerebellar granule cells.
  48. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science
  49. (2007). et al.: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
  50. (1998). et al.: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature
  51. (2003). et al.: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA
  52. (2005). et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA
  53. (2004). et al.: Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry
  54. (1999). et al.: Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.
  55. (2005). et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science
  56. (2006). Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
  57. (2007). Feany MB: Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol
  58. (2001). Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science
  59. (1994). Feinstein SC: Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau.
  60. (1996). Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol
  61. (2006). Forman MS: Impaired glutamate transport in a mouse model of tau pathology in astrocytes.
  62. (1999). Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau.
  63. (2007). G: Tau impacts on growth-factor-stimulated actin remodeling.
  64. (2002). GD: An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol
  65. (1998). GG: Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau.
  66. (1998). Ghetti B: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.
  67. (2005). Glabe CG: Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid. Biochim Biophys Acta
  68. (2002). Gong CX: Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience
  69. (2005). Gong CX: Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation.
  70. (2002). Gong CX: Involvement of aberrant glycosylation in phosphorylation of tau by
  71. (2004). Gong CX: O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
  72. (2002). Gong CX: Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
  73. (1993). Grundke-Iqbal I: Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.
  74. (2008). GV: Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticulum stress induced cell death. Brain Res
  75. (1998). GV: Tau complexes with phospholipase Cgamma in situ. Neuroreport
  76. (2006). H: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
  77. (1995). Harrington CR: Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. Neuroreport
  78. (2005). Head E: Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol
  79. (2000). Heutink P: Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Hum Mol Genet
  80. (1987). Hirano bodies contain tau protein. Brain Res
  81. (2000). Hirokawa N: Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes.
  82. (2000). Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease.
  83. (2000). Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA
  84. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.
  85. (1993). Ihara Y: Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron
  86. (1993). Imahori K: Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett
  87. (2007). Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
  88. (2007). Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP × Tau transgenic mice.
  89. (2000). Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments.
  90. (1995). Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain.
  91. (1996). Iqbal K: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med
  92. (1992). Iqbal K: Brain levels of microtubuleassociated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein.
  93. (1996). Iqbal K: Glycosylation of microtubuleassociated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med
  94. (2001). Iqbal K: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA
  95. (2006). Iqbal K: Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J Alzheimers Dis
  96. (1995). Iqbal K: Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.
  97. (2000). Iqbal K: Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.
  98. (2006). Iqbal K: Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.
  99. (2004). Iqbal K: Promotion of hyperphosphorylation by frontotemporal dementia tau mutations.
  100. (1994). Iqbal K: Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.
  101. (2001). Ischiropoulos H: Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res
  102. (2001). JM: Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol
  103. (2004). JP: Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease.
  104. (2000). JR: Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol
  105. (1999). JW: Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures. Toxicol Appl Pharmacol
  106. (2003). JZ: Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience
  107. (2005). JZ: Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. FEBS Lett
  108. (2007). Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
  109. (2004). KJ: Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease.
  110. (2004). Kosaka K: Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol
  111. (2001). Kosik KS: Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell
  112. (1990). Kosik KS: Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature
  113. (2008). KP: Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.
  114. (2000). KP: Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell
  115. (1999). KP: The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature
  116. (2004). KS: CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival.
  117. (1997). KS: Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci
  118. (1989). KS: The microtubule binding domain of tau protein.
  119. (2004). Ksiezak-Reding H: Phosphorylation of tau by fyn: implications for Alzheimer's disease.
  120. (2004). LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron
  121. (2002). LC: Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.
  122. (2002). LH: A survey of
  123. (2003). LH: Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron
  124. (2000). LI: C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.
  125. (2007). LI: Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol
  126. (2006). LI: Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.
  127. (2005). LI: Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging
  128. (1999). Liposits Z: Glycosylation of microtubule-associated protein tau in Alzheimer's disease brain. Acta Neuropathol
  129. (1999). Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett
  130. (1999). Lovestone S: Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett
  131. (2005). LS: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science
  132. (1999). M o h r M , C a l v a s P , G h e t t i B : A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol
  133. (2007). Mandelkow E, et al.: The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
  134. (1993). Mandelkow E: Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett
  135. (1995). Mandelkow E: Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262.
  136. (2007). Mandelkow EM: Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1.
  137. (1999). McGeer PL: Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA. Brain Res
  138. (2008). Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
  139. (2003). Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation.
  140. (2005). Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA
  141. (1988). ML: Light and electron microscope localization of the microtubule-associated tau protein in rat brain.
  142. (2007). Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science
  143. (1998). Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science
  144. (1975). MW: A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA
  145. (1977). MW: Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin.
  146. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet
  147. (2001). Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science
  148. (2006). number not for citation purposes) ferential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci
  149. (1988). Okabe S: Tau proteins: the molecular structure and mode of binding on microtubules.
  150. (1999). Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol
  151. (2006). Overexpression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Biochem Soc Trans
  152. (1996). Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol
  153. (2006). Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging
  154. (1998). Panchamoorthy G: Tau interacts with src-family non-receptor tyrosine kinases.
  155. (2003). Paudel HK: 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex.
  156. (1999). PD: Neurons may live for decades with neurofibrillary tangles.
  157. (2006). Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. Biochemistry
  158. (1997). Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro.
  159. (1987). Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton
  160. (2008). Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.
  161. (1999). Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry
  162. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol
  163. (1987). PO: A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.
  164. (1983). Pollard TD: Phosphorylation of microtubule-associated proteins regulates their interaction with actin filaments.
  165. (1999). Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations.
  166. (2001). PR: Chronic mitochondrial inhibition induces glutamate-mediated corticomotoneuron death in an organotypic culture model. Exp Neurol
  167. (2001). Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis
  168. (1992). Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature
  169. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.
  170. (1993). Purich DL: Microtubule-associated protein interactions with actin filaments: evidence for differential behavior of neuronal MAP-2 and tau in the presence of phosphatidyl-inositol.
  171. (2001). R: A gene expression profile of Alzheimer's disease.
  172. (1999). RA: Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments.
  173. (2006). Rasenick MM: Tau associates with actin in differentiating PC12 cells. Faseb J
  174. (1995). RB: Subpopulations of tau interact with microtubules and actin filaments in various cell types. Cell Biochem Funct
  175. (2002). RB: Tubulin, actin, and tau protein interactions and the study of their macromolecular assemblies.
  176. (2001). Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice.
  177. (1996). Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron
  178. (1996). Rhee SG: Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid.
  179. (1999). RN: Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res
  180. (2003). Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature
  181. (2005). RW: Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta
  182. (2004). S: MAP2c, but not tau, binds and bundles F-actin via its microtubule binding domain. Curr Biol
  183. (2008). SC: FTDP-17 mutations in tau alter the regulation of microtubule dynamics – an "Alternative Core" model for normal and pathological tau action.
  184. (1990). Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol
  185. (2005). Schellenberg GD: Regulation of tau isoform expression and dementia. Biochim Biophys Acta
  186. (2008). SH: A novel calcium-binding protein is associated with tau proteins in tauopathy.
  187. (1999). SH: Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett
  188. (2005). SH: Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res Mol Brain Res
  189. (2000). SH: Missense tau mutations ident i f i ed i n FT D P - 17 ha v e a s mall effect on tau-microtubule interactions. Brain Res
  190. (2000). Shea TB: Phosphorylation of tau alters its association with the plasma membrane. Cell Mol Neurobiol
  191. (2005). Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry
  192. (2005). Site-specific nitration differentially influences tau assembly in vitro. Biochemistry
  193. (2006). Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation.
  194. (2000). SK: Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly.
  195. (2001). SL: Utilizing the peptidyl-prolyl cistrans isomerase pin1 as a probe of its phosphorylated target proteins. Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain.
  196. (2007). SP: Multiplemotor based transport and its regulation by Tau. Proc Natl Acad Sci USA
  197. (2000). Spillantini MG: Tau gene mutation K257T causes a tauopathy similar to Pick's disease.
  198. (2009). ST: The amino terminus of tau inhibits kinesindependent axonal transport: Implications for filament toxicity.
  199. (1995). Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration. Neurodegeneration
  200. (1993). T: A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule.
  201. (1986). TA: Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res
  202. (1998). Takashima A: Characterization of tau phosphorylation in glycogen synthase kinase-3beta and cyclin dependent kinase5 activator (p23) transfected cells. Biochim Biophys Acta
  203. (2007). Tau aggregation and toxicity in a cell culture model of tauopathy.
  204. (2000). Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem Res
  205. (1999). Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits.
  206. (2008). Tau isoform expression and regulation in human cortical neurons. Faseb J
  207. (1993). Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
  208. (1998). Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett
  209. (2002). Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.
  210. (1999). Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol
  211. (2008). TB: Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: neurofilaments attenuate tau-mediated neurite instability. Cell Motil Cytoskeleton
  212. (2007). The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
  213. (2008). The microtubule-associated protein tau is phosphorylated by Syk. Biochim Biophys Acta
  214. (2006). The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease.
  215. (2003). Trojanowski JQ: Nitration of tau protein is linked to neurodegeneration in tauopathies.
  216. (2006). Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.
  217. (2005). Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
  218. (1987). Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA
  219. (2000). Untangling tau-related dementia. Hum Mol Genet
  220. (2008). Vanmechelen E, et al.: Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics
  221. (2001). Vitek MP: Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice.
  222. (2001). VM: PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol
  223. (2007). VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron
  224. (2008). Vocadlo DJ: A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol
  225. (2007). Wade-Martins R: Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. Neurobiol Dis
  226. (2007). Wang JZ: Effects of tau phosphorylation on proteasome activity. FEBS Lett
  227. (2001). White CL 3rd, Bigio EH: Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. Arch Neurol
  228. (2004). White CL 3rd: Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology.
  229. (1993). Wischik CM: Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.
  230. (1991). Wischik CM: Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci USA
  231. (1993). Wischik CM: Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. Embo J
  232. (1996). Wischik CM: Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol
  233. (1994). WL: Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells.
  234. (1995). Yankner BA: beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.